If lawmakers in Washington truly seek to strengthen America against all threats foreign or domestic, they must reauthorize the Pandemic and All-Hazards Preparedness Act. Isolationism is not an option with infectious diseases, and PAHPRA keeps the United States engaged and vigilant.
Two Baltimore firms will work to develop and manufacture a vaccine for the Lassa virus, a deadly emerging virus threat in Africa, under a $36 million grant from a global disease preparedness organization.
When the next flu pandemic strikes, a newly expanded pharmaceutical plant in East Baltimore now stands ready to respond. Emergent BioSolutions, in partnership with the federal government, spent $80 million to double the size of its East Lombard Street plant near Johns Hopkins Bayview Medical Center.
Federal approval for a new drug can take a decade or more, but researchers at Johns Hopkins University are studying a way to shave off years for medications meant for serious outbreaks of flu, Ebola or other infectious disease
The $1.1 billion allocated by Congress last week to target Zika will mean more money for states and localities to control and monitor for the mosquito-borne virus and for researchers to development of vaccines and diagnostic tests
With an official link established this week by the U.S. Centers for Disease Control and Prevention between Zika and birth defects, and warmer weather expected to propel the mosquito-borne virus north, the push is intensifying for a drug to prevent or treat infections
Almost a year after deploying to Liberia to help fight Ebola, soldiers with the 1st Area Medical Laboratory are still combing over the experience, looking to share tips that might help the Army better respond to major disease outbreaks in future.
Baltimore biotechnology company Profectus BioSciences is testing a vaccine to guard against the Ebola virus on 39 human subjects, a first step toward administering it more broadly in people at risk of exposure to the deadly pathogen.
Looking back at new developments in health, science, and technology this year, one thing is clear — 2015 was a banner year for medical milestones, scientific breakthroughs and technological advances at local universities and biotech companies.
Two Baltimore institutions will share in $11 million in new funding from the U.S. Center for Disease Control and Prevention aimed at preventing the spread of germs, which continues to be both a deadly and costly problem in health care settings.
Middle East Respiratory Syndrome, or MERS, is similar to another deadly coronavirus identified a decade ago called Severe Acute Respiratory Syndrome, giving scientists a jump on the investigation into their origins.
A research partnership between U.S. and Liberian health officials has launched a study to learn more about the long-term health consequences of Ebola, including why it commonly causes vision damage and eye inflammation.
The U.S. Army Edgewood Chemical Biological Center and the U.S. Army Medical Research Institute of Infectious Diseases are partnering to help expedite progress in the global fight against Ebola. ECBC is working with USAMRIID on two critical studies –a vaccine study and a biomarker study – that will advance the global fight against Ebola.
Early in the morning of Sunday, May 17, thousands of athletes will descend on Centennial Park in Ellicott City. We talked to three local competitors about the inspiring stories that led them to swim, bike and run.
With the current momentum to do more to facilitate the detection and response to viral infections, we encourage national and global public policy makers, business leaders and academic leaders to increase support for the training of the next generation of medical virologists as part of comprehensive pandemic preparedness plans.
By Robert C. Gallo, N. Scott Fine, Diane E. Griffin and Sharon H. Hrynkow
Research being published Thursday suggests that an Ebola vaccine being developed by Baltimore company Profectus BioSciences is effective against the strain of the virus that has ravaged West Africa, a milestone the company says is a first in the race to prevent future Ebola outbreaks.
Maryland residents who have been to any of the three West African countries battling an Ebola outbreak now can use their smartphone or computer to report possible symptoms to the state health department, the agency and the application's developer said Wednesday.
At its growing East Baltimore facility, Emergent BioSolutions has produced a booster shot to go with a leading Ebola vaccine candidate, joining in a competitive race to make a safe and effective tool to stop the spread of an outbreak that continues in West Africa and to prevent future outbreaks.
Four Web-based training videos developed by Johns Hopkins Medicine and others aim to train doctors, nurses and other medical professionals in the proper way to handle patients who show up at their hospitals with serious infectious diseases.
Thousands of people are to be injected with two experimental Ebola vaccines in trials in West Africa within a couple of weeks, and a Baltimore biotechnology company is launching a human trial of its own candidate in June, as scientists and public health officials work to end the deadly epidemic.
As I work with dozens of donors and partners on the Ebola frontlines in Liberia, it's difficult to accept news reports of rampant disorganization, poor planning and infighting. These dispatches may reflect the initial challenges of pooling our resources in the most productive ways, but they have not told the entire story of the work taking place in Liberia in the battle against Ebola. My colleagues and I are working in harmony with one another and with Liberia's Ministry of Health. What's more,